Stockscreener 앱 받기
0.3647
4.19%
0.0147
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Price to earnings forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 5%Margin Compression Risk - dars.gov.et
NXL Should I Buy - Intellectia AI
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com - Investing.com South Africa
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split - Stock Titan
NexaLine Technology Registers 1.2 Million Shares for Resale - Moomoo
Nexalin Technology | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia - Sleep Review
Nexalin Technology, Inc. Actuals & Estimates (NASDAQ:NXL) - TradingView
$Nexalin Technology (NXL.US)$ - Moomoo
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NXL Forecast — Price Target — Prediction for 2027 - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL Stock Price, Quote & Chart - ChartMill
Nexalin Technology Announces that the Investigator of Its - GlobeNewswire
Nexalin Brazil sleep trial earns award at brain congress - Stock Titan
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin Technology, Inc. Financial Disclosures & SEC Filings - TradingView
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXLIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXLIW) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXLIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026 - Minichart
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework - TipRanks
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules - Stock Titan
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com - Investing.com South Africa
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXLIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference - marketscreener.com
Nexalin abstracts accepted at NYC neuromodulation conference - Investing.com
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - Yahoo Finance
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Amid Continued Development PhaseEarnings Outlook Update - newsline.com
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial - Moomoo
Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression - Quiver Quantitative
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sale - 富途牛牛
Nexalin receives U.S. patent for neurostimulation method - Investing.com UK
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - markets.businessinsider.com
Nexalin receives U.S. patent for neurostimulation method By Investing.com - Investing.com South Africa
0.43%
0.38%
자본화:
|
볼륨(24시간):